Mounjaro denials in California external review
In the California DMHC record, independent physician reviewers decided 170 published external-review cases involving Mounjaroand overturned the plan’s denial in 68.8%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Obesity | 58 | 58.6% |
| Type 2 Diabetes Mellitus | 57 | 82.5% |
| Type 2 Diabetes | 41 | 78% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 143 | 71.3% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 27 | 55.6% |
What the reviewers wrote
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Mounjaro. A researcher explains, “Tirzepatide (Mounjaro™) is a single molecule that combines dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Native GIP and GLP-1 are incretin hormones that stimulate insulin secretion and decrease glucagon secretion. GIP also plays a role in nutrient and energy metabolism, while GLP-1 also delays gastric emptying, suppresses appetite, and improves satiety. Eli Lilly is developing tirzepatide for the treatment of type 2 diabetes mellitus (T2DM), obesity, cardiovascular disorders in T2DM, heart failure, non-alcoholic steatohepatitis, obstructive sleep apnea and for reducing mortality/morbidity in obesity.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Mounjaro Solution Pen-injectable 5 mg/0.5ML (once a week).The use of glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of type 2 diabetes is supported by guidelines from both the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE) (Blonde, L., et al.; ElSayed, N., et al.). These guidelines recommend GLP-1 receptor agonists as a second-line or adjunctive therapy for individuals with type 2 diabetes who are not adequately controlled on metformin or for whom metformin is contraindicated. GLP-1 receptor agonists work by increasing insulin secretion, reducing glucagon secretion, and slowing gastric emptying.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Mounjaro. Diabetes mellitus is a common, albeit potentially devastating, medical condition that has increased in prevalence over the past few decades to constitute a major public health challenge in the twenty-first century. The mortality rate for patients with diabetes is one and a half times higher than for individuals without diabetes. Tirzepatide (brand name Mounjaro), a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus, along with diet and exercise, based on clinical data demonstrating that tirzepatide is superior to placebo in improving hemoglobin (Hb) A1C levels.
Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Mounjaro. Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. The U.S. Food and Drug Administration (FDA) approved tirzepatide under the brand name Mounjaro in May 2022 for the treatment of patients with type 2 diabetes mellitus. The FDA’s approval was based on the SURPASS-1 clinical trial, which demonstrated that tirzepatide is superior to placebo in improving hemoglobin A1c levels. Subsequent SURPASS clinical trials also showed great effectiveness in weight reduction, although they were designed with the primary aim of observing glycemic control. The Surmount 1 clinical trial assessed the safety and efficacy of tirzepatide for weight loss in patients with obesity.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
Why plans deny Mounjaro — and what reviewed cases show
Mounjaro (tirzepatide) is FDA-approved for: type 2 diabetes. An on-label indication can be important evidence when a denial frames the requested use as unproven or cosmetic.
Indication mismatch — the defining Mounjaro denial
Mounjaro is approved for type 2 diabetes. The same molecule, tirzepatide, is approved for weight management under the name Zepbound. Plans deny Mounjaro hard when the diagnosis on the claim is obesity rather than diabetes — and the published review outcomes show off-label weight-loss requests fare far worse than diabetes requests. If weight management is the goal, the on-label route is Zepbound, and prescriptions written that way put you on much stronger appeal footing.
“Try metformin first” step therapy
For type 2 diabetes, formularies typically require metformin and often a second agent before a GLP-1 class drug. Denials cite missing documentation of those trials more often than any clinical judgment about you.
A1C and diagnosis documentation
Approvals lean on chart-documented A1C values and a coded type 2 diabetes diagnosis. Prediabetes-coded requests are routinely denied — and the published record shows reviewers usually side with plans there.
Diabetes step-therapy requirements yield to documented failure or intolerance of preferred agents. Have your prescriber submit a step-therapy exception citing specific prior trials rather than re-arguing medical necessity from scratch.
Evidence cited in overturned Mounjaro decisions
- If you have type 2 diabetes, make the record show it plainly: diagnosis codes, A1C history, current regimen, and what prior agents failed to control.
- Document metformin (and other prior-agent) trials — doses, duration, outcome, side effects — to close out the step-therapy rationale.
- If the prescription is really for weight management without diabetes, talk to your prescriber about the on-label tirzepatide product; appeals for on-label use win dramatically more often.
- For continuation denials: prior authorization already granted plus documented clinical benefit is a strong basis — plans need a reason to un-approve working therapy.
The published California record contains 170 external-review decisions involving Mounjaro; 68.8% were overturned. This historical rate does not predict another case. For the full class-wide picture — cross-indication strategy, exclusion language, and the record for every GLP-1 drug — see the GLP-1 denial appeal guide.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Mounjaro, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY